US Stock MarketDetailed Quotes

TNXP Tonix Pharmaceuticals

Watchlist

0.1899
+0.0011+0.58%

Trading Nov 27 12:33 ET

35.49MMarket Cap-2P/E (TTM)

Tonix Pharmaceuticals Stock Forum

Angelos

32 minutes ago

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Angelos

35 minutes ago

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

1 hour ago

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

1 hour ago

$Tonix Pharmaceuticals (TNXP.US)$ https://youtu.be/v_VIj3lMETU?si=mKwShpRtJb54IFS2

我要向钱看

1 hour ago

CONTINUE FROM PREVIOUS UPDATE

$Tonix Pharmaceuticals (TNXP.US)$ Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ:TNXP), joined Steve Darling from Proactive to unveil promising results at the ACR Convergence 2024 Annual Meeting from the company’s Phase 3 RESILIENT trial of its proprietary sublingual bedtime medication for fibromyalgia. The trial met its primary endpoint, achieving a statistically significant reduction in daily pain compared to a placebo.
Additionally, the treatment demonstr...